Active ingredientsDosage formQuantity of active ingredientsShortage statusAvailabilityReasonLast updated
| human menopausal gonadotrophin | Injection, powder for | 600 IU | Resolved | Available | Manufacturing | 2/03/2026 |
| lamotrigine | Tablet, chewable | 200 mg | Anticipated | Available | Manufacturing | 2/03/2026 |
| lamotrigine | Tablet, chewable | 100 mg | Anticipated | Available | Manufacturing | 2/03/2026 |
| estradiol | Drug delivery system, transdermal | 1.17 mg | Current | Limited Availability | Manufacturing | 2/03/2026 |
| amidotrizoate meglumine~sodium amidotrizoate | Injection, solution | 260 mg/mL~40 mg/mL | Current | Unavailable | Manufacturing | 2/03/2026 |
| sodium amidotrizoate~amidotrizoate meglumine | Injection, intravenous infusion | 40 mg/mL~260 mg/mL | Current | Unavailable | Manufacturing | 2/03/2026 |
| amlodipine besilate~hydrochlorothiazide~olmesartan medoxomil | Tablet, film coated | 13.9 mg~12.5 mg~40 mg | Anticipated | Available | Manufacturing | 2/03/2026 |
| amidotrizoate meglumine~sodium amidotrizoate | Oral Liquid, solution | 66 g~10 g | Current | Unavailable | Manufacturing | 2/03/2026 |
| bupivacaine hydrochloride | Injection, solution | 5 mg/mL | Anticipated | Available | Manufacturing | 2/03/2026 |
| calcitonin salmon | Injection, solution | 100 IU/mL | Current | Limited Availability | Unexpected increase in consumer demand | 2/03/2026 |
| human menopausal gonadotrophin | Injection, powder for | 1200 IU | Resolved | Available | Manufacturing | 2/03/2026 |
| atomoxetine hydrochloride | Capsule, hard | 20.57 mg | Resolved | Available | Manufacturing | 2/03/2026 |
| doxepin hydrochloride | Capsule, hard | 28.25 mg | Current | Unavailable | Manufacturing | 2/03/2026 |
| ropivacaine hydrochloride | Injection, solution | 400 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 2/03/2026 |
| flecainide acetate | Tablet, uncoated | 50 mg | Current | Unavailable | Manufacturing | 2/03/2026 |
| sodium chloride | Injection, solution | .45 g | Current | Unavailable | Commercial Changes / Commercial viability | 2/03/2026 |
| Somatropin | Injection, powder for | 5 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 2/03/2026 |
| rasagiline mesilate | Tablet | 1.56 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| crisaborole | Ointment | 2 % w/w | Current | Limited Availability | Unexpected increase in consumer demand | 27/02/2026 |
| sumatriptan succinate | Tablet, film coated | 69.99 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| indapamide hemihydrate | Tablet, sugar coated | 2.5 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| moclobemide | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| mirtazapine | Tablet, orally disintegrating | 45 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Resolved | Available | Manufacturing | 27/02/2026 |
| trandolapril | Capsule | 4 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| trandolapril | Capsule | 2 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 27/02/2026 |
| deferasirox | Tablet, film coated | 180 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| cabazitaxel | Injection, concentrated | 60 mg | Resolved | Available | Manufacturing | 27/02/2026 |
| lamotrigine | Tablet, chewable | 50 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| risperidone | Tablet, film coated | 3 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| latanoprost | Eye Drops, solution | .05 mg/mL | Current | Unavailable | Manufacturing | 27/02/2026 |
| valaciclovir hydrochloride | Tablet, film coated | 611.22 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| valaciclovir hydrochloride | Tablet, film coated | 611.22 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| moxonidine | Tablet, film coated | 200 microgram | Anticipated | Available | Unexpected increase in consumer demand | 27/02/2026 |
| sildenafil citrate | Tablet, film coated | 28.1 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| phenobarbital | Tablet, uncoated | 30 mg | Resolved | Available | Manufacturing | 27/02/2026 |
| quetiapine fumarate | Tablet, modified release | 172.695 mg | Resolved | Available | Manufacturing | 27/02/2026 |
| candesartan cilexetil~hydrochlorothiazide | Tablet | 32 mg~25 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 182 microgram/mL | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 27/02/2026 |
| clindamycin hydrochloride | Capsule, hard | 162.87 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| lamotrigine | Tablet, chewable | 25 mg | Resolved | Available | Manufacturing | 27/02/2026 |
| pemetrexed disodium | Injection, powder for | 1102.9 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| acarbose | Tablet | 100 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| olanzapine | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| ambrisentan | Tablet, film coated | 5 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 27/02/2026 |
| lanreotide acetate | Injection, solution | 100 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| clobetasol propionate | Application | .05 % w/v | Resolved | Available | Unexpected increase in consumer demand | 27/02/2026 |
| irbesartan | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| tenofovir disoproxil fumarate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| bimatoprost | Eye Drops | .3 mg/mL | Resolved | Available | Manufacturing | 27/02/2026 |
| lanreotide acetate | Injection, solution | 66.67 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 27/02/2026 |
| betiatide | Injection, powder for | 1 mg | Current | Unavailable | Manufacturing | 27/02/2026 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 20.51 mg~16 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 27/02/2026 |
| nitrofurantoin | Capsule, hard | 100 mg | Current | Limited Availability | Unexpected increase in consumer demand | 27/02/2026 |
| daunorubicin hydrochloride | Injection, powder for | 20 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| ezetimibe | Tablet, uncoated | 10 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Current | Unavailable | Manufacturing | 27/02/2026 |
| cetrimide~chlorhexidine gluconate | Solution, irrigation | 45 mg~4.5 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| ziprasidone hydrochloride monohydrate | Capsule, hard | 22.65 mg | Anticipated | Available | Manufacturing | 27/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 27/02/2026 |
| mupirocin calcium | Cream | 21.5 mg/g | Current | Limited Availability | Manufacturing | 27/02/2026 |
| levothyroxine sodium | Tablet, uncoated | .075 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 27/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 10 mg/mL | Current | Unavailable | Manufacturing | 27/02/2026 |
| live varicella vaccine | Injection, powder for | 2700 PFU/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 27/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Unavailable | Manufacturing | 27/02/2026 |
| cetrimide~chlorhexidine gluconate | Solution, irrigation | 150 mg~15 mg | Current | Limited Availability | Manufacturing | 27/02/2026 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet | 12.5 mg~40 mg | Current | Unavailable | Manufacturing | 26/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 10 mg/mL | Current | Limited Availability | Manufacturing | 26/02/2026 |
| stiripentol | Capsule | 500 mg | Resolved | Available | Manufacturing | 26/02/2026 |
| live varicella vaccine | Injection, powder for | 4000 PFU/mL | Current | Only available under NIP or government programs | Unexpected increase in consumer demand | 26/02/2026 |
| cinacalcet hydrochloride | Tablet, film coated | 99 mg | Current | Unavailable | Manufacturing | 26/02/2026 |
| pantoprazole sodium sesquihydrate | Tablet, enteric coated | 45.4 mg | Current | Limited Availability | Unexpected increase in consumer demand | 26/02/2026 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Limited Availability | Manufacturing | 26/02/2026 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Limited Availability | Manufacturing | 26/02/2026 |
| naratriptan hydrochloride | Tablet, film coated | 2.78 mg | Resolved | Available | Manufacturing | 26/02/2026 |
| gabapentin | Capsule, hard | 300 mg | Resolved | Available | Manufacturing | 26/02/2026 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 26/02/2026 |
| alprostadil | Injection, powder for | 40 microgram/mL | Current | Limited Availability | Manufacturing | 26/02/2026 |
| dapsone | Tablet, uncoated | 25 mg | Anticipated | Available | Manufacturing | 26/02/2026 |
| rifabutin | Capsule, hard | 150 mg | Anticipated | Available | Manufacturing | 26/02/2026 |
| dabigatran etexilate mesilate | Capsule, hard | 172.95 mg | Current | Unavailable | Manufacturing | 26/02/2026 |
| dapsone | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 26/02/2026 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Unavailable | Manufacturing | 26/02/2026 |
| deferasirox | Tablet, film coated | 180 mg | Current | Limited Availability | Manufacturing | 26/02/2026 |
| dimethyl fumarate | Capsule, enteric | 240 mg | Current | Unavailable | Manufacturing | 26/02/2026 |
| metformin hydrochloride | Tablet, modified release | 1000 mg | Current | Limited Availability | Manufacturing | 26/02/2026 |
| desmopressin acetate | Spray, solution | .1 mg/mL | Current | Unavailable | Product recall | 25/02/2026 |
| carbetocin | Injection, solution | 100 microgram/mL | Anticipated | Available | Manufacturing | 25/02/2026 |
| cisatracurium besilate | Injection, solution | 7.04 mg | Resolved | Available | Manufacturing | 25/02/2026 |
| betahistine dihydrochloride | Tablet, uncoated | 16 mg | Resolved | Available | Unexpected increase in consumer demand | 25/02/2026 |
| olanzapine | Tablet, orally disintegrating | 10 mg | Current | Limited Availability | Manufacturing | 25/02/2026 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.688 mg | Current | Limited Availability | Manufacturing | 25/02/2026 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.376 mg | Current | Limited Availability | Manufacturing | 25/02/2026 |
| azacitidine | Injection, powder for | 100 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 25/02/2026 |
| atorvastatin calcium trihydrate | Tablet, film coated | 10.844 mg | Current | Limited Availability | Manufacturing | 25/02/2026 |
| perindopril erbumine~indapamide hemihydrate | Tablet | 4 mg~1.25 mg | Current | Unavailable | Manufacturing | 25/02/2026 |
| lamivudine | Tablet, film coated | 300 mg | Current | Unavailable | Manufacturing | 25/02/2026 |
| avanafil | Tablet, uncoated | 200 mg | Resolved | Available | Unexpected increase in consumer demand | 25/02/2026 |
| amlodipine besilate~atorvastatin calcium trihydrate | Tablet, film coated | 13.88 mg~86.751 mg | Current | Limited Availability | Manufacturing | 25/02/2026 |
| risperidone | Tablet, film coated | 3 mg | Current | Unavailable | Manufacturing | 25/02/2026 |
| levothyroxine sodium | Tablet, uncoated | .2 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 25/02/2026 |
| Hepatitis B surface antigen recombinant | Injection, suspension | 40 microgram/mL | Anticipated | Available | Unexpected increase in consumer demand | 25/02/2026 |
| gabapentin | Capsule, hard | 400 mg | Resolved | Available | Manufacturing | 25/02/2026 |
| ondansetron hydrochloride dihydrate | Injection, solution | 5 mg | Current | Unavailable | Manufacturing | 25/02/2026 |
| ondansetron hydrochloride dihydrate | Injection, solution | 10 mg | Current | Unavailable | Manufacturing | 25/02/2026 |
| telmisartan~amlodipine besilate | Tablet, multilayer | 40 mg~6.935 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| lacosamide | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 24/02/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Resolved | Available | Manufacturing | 24/02/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Resolved | Available | Unexpected increase in consumer demand | 24/02/2026 |
| amlodipine besilate~telmisartan | Tablet, multilayer | 6.935 mg~80 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| clonidine hydrochloride | Injection, solution | 150 microgram/mL | Current | Limited Availability | Unexpected increase in consumer demand | 24/02/2026 |
| entacapone~carbidopa monohydrate~levodopa | Tablet, film coated | 200 mg~27 mg~100 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 24/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 20 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 24/02/2026 |
| olipudase alfa | Injection, powder for | 20 mg | Current | Limited Availability | Manufacturing | 24/02/2026 |
| flunitrazepam | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 24/02/2026 |
| ropivacaine hydrochloride | Injection, solution | 10 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 24/02/2026 |
| telmisartan~amlodipine besilate | Tablet, multilayer | 40 mg~13.87 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| lamotrigine | Tablet, dispersible | 200 mg | Resolved | Available | Manufacturing | 24/02/2026 |
| amlodipine besilate~telmisartan | Tablet, multilayer | 6.935 mg~80 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| amlodipine besilate~telmisartan | Tablet, multilayer | 13.87 mg~40 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| nizatidine | Capsule | 300 mg | Resolved | Available | Manufacturing | 24/02/2026 |
| amlodipine besilate~telmisartan | Tablet, multilayer | 13.87 mg~80 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| telmisartan~amlodipine besilate | Tablet, multilayer | 40 mg~6.935 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 24/02/2026 |
| sunitinib | Capsule | 25 mg | Anticipated | Available | Manufacturing | 24/02/2026 |
| posaconazole | Tablet, modified release | 100 mg | Current | Limited Availability | Manufacturing | 24/02/2026 |
| dabigatran etexilate mesilate | Capsule, hard | 126.83 mg | Current | Limited Availability | Manufacturing | 24/02/2026 |
| aprepitant | Capsule, hard | 165 mg | Anticipated | Available | Manufacturing | 24/02/2026 |
| bromocriptine mesilate | Tablet, uncoated | 2.87 mg | Current | Unavailable | Manufacturing | 24/02/2026 |
| peramivir | Injection, concentrated | 10 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 24/02/2026 |
| carbidopa monohydrate~levodopa | Tablet, uncoated | 26.9 mg~100 mg | Resolved | Available | Manufacturing | 24/02/2026 |
| amlodipine besilate~telmisartan | Tablet, multilayer | 13.87 mg~80 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| drospirenone~ethinylestradiol | Tablet | 3 mg~30 microgram | Current | Limited Availability | Manufacturing | 24/02/2026 |
| cabergoline | Tablet, uncoated | 2 mg | Anticipated | Available | Manufacturing | 24/02/2026 |
| silver sulfadiazine | Cream | 10 mg/g | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| telmisartan~amlodipine besilate | Tablet, film coated | 40 mg~6.935 mg | Discontinued | Reduction in supply until supply is exhausted | Unexpected increase in consumer demand | 24/02/2026 |
| telmisartan~amlodipine besilate | Tablet, film coated | 80 mg~13.87 mg | Discontinued | Reduction in supply until supply is exhausted | Unexpected increase in consumer demand | 24/02/2026 |
| amlodipine besilate~telmisartan | Tablet, film coated | 6.935 mg~80 mg | Discontinued | Reduction in supply until supply is exhausted | Unexpected increase in consumer demand | 24/02/2026 |
| amlodipine besilate~telmisartan | Tablet, film coated | 13.87 mg~40 mg | Discontinued | Reduction in supply until supply is exhausted | Unexpected increase in consumer demand | 24/02/2026 |
| isotretinoin | Capsule, soft | 20 mg | Current | Unavailable | Manufacturing | 24/02/2026 |
| silver sulfadiazine | Cream | 10 mg/g | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/02/2026 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 54.1 mg~200 mg~200 mg | Current | Unavailable | Unexpected increase in consumer demand | 24/02/2026 |
| fluorouracil | Injection, solution | 50 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 23/02/2026 |
| olanzapine | Tablet, orally disintegrating | 20 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 23/02/2026 |
| aripiprazole | Tablet, uncoated | 20 mg | Anticipated | Available | Manufacturing | 23/02/2026 |
| cyproterone acetate | Tablet, uncoated | 50 mg | Current | Limited Availability | Manufacturing | 23/02/2026 |
| olipudase alfa | Injection, powder for | 4 mg | Resolved | Available | Manufacturing | 23/02/2026 |
| rifampicin | Capsule | 150 mg | Resolved | Available | Manufacturing | 23/02/2026 |
| olanzapine | Tablet, orally disintegrating | 5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 23/02/2026 |
| simvastatin~ezetimibe | Tablet | 40 mg~10 mg | Current | Limited Availability | Manufacturing | 23/02/2026 |
| simvastatin | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 23/02/2026 |
| nicorandil | Tablet, uncoated | 20 mg | Resolved | Available | Manufacturing | 23/02/2026 |
| tobramycin | Injection, solution | 80 mg | Resolved | Available | Manufacturing | 23/02/2026 |
| alprostadil | Injection, powder for | 20 microgram/mL | Resolved | Available | Unexpected increase in consumer demand | 23/02/2026 |
| atomoxetine hydrochloride | Capsule, hard | 11.43 mg | Current | Unavailable | Manufacturing | 23/02/2026 |
| rifampicin | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 23/02/2026 |
| formoterol fumarate | Inhalation, powder for | 12 microgram | Current | Limited Availability | Manufacturing | 23/02/2026 |
2026年3月2日